2 months ago
By MC2 Therapeutics
Published [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year]
MC2 Therapeutics to Present astatine Upcoming Conferences
Copenhagen, February 26th, 2024 – MC2 Therapeutics, a commercialized shape biotech institution focused connected processing caller curen paradigms wrong immunology and inflammation, announces coming that its activity will be and coming astatine nan pursuing manufacture conferences:
- 17th Annual European Life Sciences CEO Forum, Zürich February 28th-29th (presentation astatine 3:20pm CET, February 28th - Track C - Room Panorama C)
- TD Cowen Annual Health Care Conference, Boston March 4th-6th (hosting 1:1 meetings pinch investors connected March 4th astatine nan event)
- American Academy of Dermatology Annual Meeting, San Diego March 8th-12th
- Kempen Life Science Conference, Amsterdam April 16th-17th (presentation connected April 16th)
Bio€quity Europe, San Sebastian May 12th-14th (presentation clip and location to beryllium announced)
Any webcasts will beryllium disposable connected MC2’s website pursuing nan presentations. Please interaction america if you would for illustration to put a meeting.
About MC2 Therapeutics
MC2 Therapeutics is simply a commercialized shape biotech institution focused connected processing caller curen paradigms wrong immunology and inflammation. Its pioneering attack successful immunology is anchored successful a heavy knowing of tegument biology, objective expertise and cross-silo thinking.
Its pipeline includes 2 first-in-class supplier candidates some successful Phase 2 objective development, pinch caller modes of action and blockbuster imaginable successful aggregate indications (“I&I pipeline successful a product”):
MC2-32: an oral HSP90 inhibitor pinch unsocial insubstantial circumstantial targeting and a caller MOA that modulates aggregate pro-inflammatory pathways and applicable immune responses.
MC2-25: an iso-cyanate scavenger addressing carbamylation of proteins and amino acids successful nan tegument by iso-cyanate, a dissociation merchandise of urea.
For further accusation connected MC2 Therapeutics, please sojourn www.mc2therapeutics.com.
Contacts:
Lonni Goltermann, +45 2018 1111, [email protected]
Media: ICR Consilium
Amber Fennell, +44 20 3709 5700, [email protected]
